EP-1375: Volumetric-modulated-arc-therapy versus 3D-conformal-radiotherapy for sarcoma of extremities
A.M. Ascolese(IRCCS Humanitas Research Hospital), Marta Scorsetti(Humanitas University), Vittorio Quagliuolo(Humanitas University), Antonella Fogliata(IRCCS Humanitas Research Hospital), Rita De Sanctis(Humanitas University), Andrea Marrari(IRCCS Humanitas Research Hospital), Stefano Tomatis(IRCCS Humanitas Research Hospital), Pierina Navarria(IRCCS Humanitas Research Hospital), Pietro Mancosu(Fondazione Humanitas per la Ricerca), Piergiuseppe Colombo(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), Giuseppe Roberto D’Agostino(Humanitas University), Davide Franceschini(IRCCS Humanitas Research Hospital)
Cited by 0
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646